TORONTO, March 21, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has successfully completed an international shipment of LaNeo™ MDMA to the University of Washington, USA. This continues the fulfillment of orders from important human research studies in the United States that have chosen to use Phamala’s pharmaceutical grade LaNeo™ MDMA capsules for their clinical research.
“While we’re incredibly pleased to have delivered a supply of LaNeo™ MDMA to the University of Washington, it has become apparent that US-Canada cross-border trade uncertainty is an ongoing risk for clients,” said Dr. Shane Morris, COO, PharmAla Biotech. “As a result, the PharmAla team is working hard to mitigate such uncertainty , and we look forward to announcing a solution soon.”
Pharmala notes that is regrettable that important US research is detrimentally impacted by tariffs, and calls for all investigational drug products destined for US funded health research studies at US institutions to be exempt from tariffs. By global convention, all investigational drugs destined for clinical research are usually shipped tariff-free.
Appointment of Ali Taghva as Chief Commercial Officer
PharmAla is furthermore pleased to announce that Mr. Ali Taghva will take on new responsibilities, acting as Chief Commercial Officer to the Company, as well as Counsel to the Company.
For more information, please visit www.PharmAla.ca, where you can sign up to receive regular news updates.
PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla’s research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.
For more information, please contact:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca